<div id="readability-page-1"><div><div>U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.Shares of Ultragenyx Pharmaceutical Inc. RARE fell sharply in pre-market trading.Ultragenyx received a Complete Response Letter from the FDA for UX111 AAV gene therapy to treat Sanfilippo Syndrome Type A (MPS IIIA).Ultragenyx Pharmaceutical shares dipped 8% to $27.15 in the pre-market trading session.<div><div><h3>Trending Investment Opportunities</h3></div></div>Here are some other stocks moving lower in pre-market trading.<ul> <li>MiNK Therapeutics, Inc. INKT shares tumbled 31% to $44.25 in pre-market trading. MiNK Therapeutics shares jumped 730% on Friday after the company announced a publication in Oncogene.</li> <li>Above Food Ingredients Inc. ABVE shares dipped 21.3% to $2.84 in pre-market trading after jumping 134% on Friday. Above Food Ingredients recently announced a merger agreement with Palm Global.</li> <li>Newegg Commerce, Inc. NEGG declined 11.3% to $43.66 in pre-market trading after gaining 71% on Friday.</li> <li>CEL-SCI Corporation CVM shares dipped 11% to $3.08 in pre-market trading after declining 8% on Friday. CEL-SCI recently announced it signed a partnership with a Saudi Arabian pharma and healthcare company.</li> <li>Unusual Machines, Inc. UMAC slipped 8% to $11.13 in pre-market trading after gaining 39% on Friday.</li> <li>Gossamer Bio, Inc. GOSS declined 6.6% to $1.2700 in pre-market trading. Gossamer Bio, last month, completed enrollment in its registrational Phase 3 PROSERA study for pulmonary arterial hypertension</li> <li>Gilat Satellite Networks Ltd. GILT fell 4.1% to $7.22 in pre-market trading. Gilat Satellite Networks recently announced its commercial division received over $22 million in orders from satellite operators.</li> <li>KalVista Pharmaceuticals, Inc. KALV dipped 4% to $13.94 in pre-market trading after falling 6% on Friday. KalVista Pharma recently posted a wider-than-expected quarterly loss.</li> <li>Apple Inc. AAPL fell 1% to $209.22 in pre-market trading. Apple is in the midst of a significant management reshuffle. Despite the company's biggest crisis in years, CEO Tim Cook remains firmly at the helm.</li> </ul>Now Read This: <ul> <li>Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</li> </ul>Photo via Shutterstock</div></div></div>

AAPL

RARE

U.S. stock futures declined this morning, with Dow futures down about 100 points. Ultragenyx Pharmaceutical Inc. shares fell 8% to $27.15 after receiving a Complete Response Letter from the FDA for its gene therapy. Other notable declines include MiNK Therapeutics down 31%, Above Food Ingredients down 21.3%, and Newegg Commerce down 11.3%. Apple Inc. shares dipped 1% amid a management reshuffle. Overall, several stocks are experiencing significant pre-market losses following recent gains.

- U.S. stock futures declined this morning, with Dow futures dropping approximately 100 points.  
- Ultragenyx Pharmaceutical Inc. shares fell 8% to $27.15 after receiving a Complete Response Letter from the FDA regarding its gene therapy for Sanfilippo Syndrome Type A.  
- Other notable declines included MiNK Therapeutics, which tumbled 31%, and Newegg Commerce, which decreased 11.3%, following significant gains in the previous trading session.  

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session